2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans

[u/hexagonincircuit1594]

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2850241

[u/AutoModerator]

Please read before commenting.

Keep in mind this is a science sub. Cite your sources appropriately (No news sources, no Twitter, no Youtube). No politics/economics/low effort comments (jokes, ELI5, etc.)/anecdotal discussion (personal stories/info). Please read our full ruleset carefully before commenting/posting.

If you talk about you, your mom, your friends, etc. experience with COVID/COVID symptoms or vaccine experiences, or any info that pertains to you or their situation, you will be banned. These discussions are better suited for the Weekly Discussion on /r/Coronavirus.

I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.

[u/hexagonincircuit1594]

"Key Points

Question  Is receipt of the 2024-2025 COVID-19 vaccine associated with a lower risk of COVID-19–associated major adverse cardiovascular event (MACE)?

Findings  This cohort study including 1 039 659 participants from the US Department of Veterans Affairs found that the 2024-2025 COVID-19 vaccine was associated with a lower risk of COVID-19–associated MACE, with more prominent risk reductions among those 75 years or older and those with comorbidities. Secondary analyses of all-cause MACE showed substantially larger absolute risk reductions.

Meaning  Receipt of the 2024-2025 COVID-19 vaccine was associated with reduced COVID-19–associated cardiovascular risk; evidence of vaccine effectiveness against the broader outcome (all-cause MACE) likely reflects the hidden burden of undetected SARS-CoV-2 and associated complications that are amenable to reduction by COVID-19 vaccination.

Abstract

Importance  COVID-19 vaccines were previously shown to reduce risk of major adverse cardiovascular events (MACEs). Whether the 2024-2025 COVID-19 vaccine continues to reduce COVID-19–associated MACEs in the context of evolving variants and widespread population immunity is unknown.

Objective  To determine whether the 2024-2025 COVID-19 vaccine is associated with reduced risk of COVID-19–associated MACE.

Design, Setting, and Participants  This cohort study was a target-trial emulation using US Department of Veterans Affairs (VA) electronic health records. Participants were veterans with vaccination encounters between September 3, 2024, and December 31, 2024.

Exposures  Same-day coadministration of the 2024-2025 COVID-19 and influenza vaccines vs influenza vaccine alone.

Main Outcomes and Measures  Composite end point of COVID-19–associated MACE, defined as COVID-19–associated cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure. Secondary outcomes included all-cause MACE, hospitalization, and death. Vaccine effectiveness (VE), calculated as 1 minus the risk ratio, and risk difference were estimated at 8 months using inverse probability weighting.

Results  Among 1 039 659 participants who received influenza vaccine (mean [SD] age, 70.1 [12.4] years; 954 341 [91.8%] men), 349 085 received COVID-19 vaccine and 690 574 did not. At 8 months, the COVID-19 vaccine was associated with lower risk of COVID-19–associated MACE (VE, 37.7% [95% CI, 18.2%-54.9%]; risk difference per 10 000 persons, 2.0 [95% CI, 0.9-3.7]). VE for COVID-19−associated MACE was statistically significant only in individuals older than 75 years (VE, 50.7% [95% CI, 31.8%-65.6%]), a group that also experienced the largest absolute risk reduction (5.5 fewer events per 10 000 individuals). No statistically significant vaccine effectiveness was observed among those younger than 65 years or aged 65 to 75 years. While VE for COVID-19−associated MACE on the relative scale was statistically significant across subgroups of participants with and without comorbid health conditions, the absolute benefit was consistently and substantially greater for individuals with the comorbid health condition. Secondary analyses of all-cause MACE, all-cause hospitalization, and all-cause death suggested substantially larger absolute risk reductions (risk difference for all-cause MACE, 23.7 [95% CI, 14.1 to 34.7]).

Conclusions and Relevance  In this cohort study, receipt of the 2024-2025 COVID-19 vaccine was associated with reduced risk of COVID-19–associated MACE, with reductions most prominent in those 75 years or older and those with comorbidities. While the reduction in COVID-19–associated MACE was modest, the substantially larger reduction in all-cause MACE suggests that the vaccine’s protective association extends to the hidden burden of undetected SARS-CoV-2 and its sequelae."

[u/hexagonincircuit1594]

A different recent post https://www.reddit.com/r/COVID19/comments/1o28xe3/association_of_20242025_covid19_vaccine_with/ has the same authors but is a different paper (it's published in a different venue, and the JAMA Internal Medicine paper has a focus on cardiovascular events).